Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
32.4 HKD | +5.88% | +14.49% | -8.22% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-8.22% | 2.61B | B | ||
-20.16% | 16.21B | B+ | ||
+4.50% | 12.44B | B | ||
+3.98% | 11.58B | B+ | ||
+9.72% | 10.79B | B+ | ||
+23.61% | 8.26B | B | ||
-2.19% | 7.68B | A- | ||
+20.75% | 7.2B | D | ||
+4.49% | 6.67B | B- | ||
+50.89% | 4.66B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 6078 Stock
- Ratings Hygeia Healthcare Holdings Co., Limited